We and others have isolated NDEVs via immunoprecipitation targeting the neuronal cell-adhesion molecule L1CAM and have shown that NDEVs can be leveraged as a diagnostic tool for AD and other neurological disorders [16–19] and as surrogates of target engagement in clinical trials [20], including trials in AD [21]. Here, NRCAM is linked to Alzheimer disease.